Roche later made changes to the trial design, although the company said overall results support further testing.

The transaction, seen as a vote of confidence, has put the focus on other drug firms testing similar barrier-bridging ...

An Alzheimer’s drug from Roche cleared a protein that’s a hallmark of the disease from patients’ brains, suggesting the drug ...

An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Roche revealed early-stage data for a new Alzheimer’s program on Wednesday as it seeks to jump back into a field littered ...

With the formation of a new strategic partnership, Dyno Therapeutics is responsible for the development of novel AAV capsids.

Biogen BIIB reported third-quarter 2024 adjusted earnings per share (EPS) of $4.08, which beat the Zacks Consensus Estimate of $3.77. While earnings declined 6% year over year on a reported basis, it ...

Q3 2024 Earnings Call Transcript October 30, 2024 8:30 AM ETCompany ParticipantsStephen Amato - Senior Director of ...

Protein Diagnostics MarketAccording to a recent analysis by Future Market Insights (FMI), the global protein diagnostics market is poised for substantial growth over the coming decade, with an ...

ABC News reports a 17.5% increase in asthma-related hospitalization in the three months after Flovent was discontinued and a 24.1% increase in the next three to six months. Other pharma news covers ...